The tests are based on the company's ICE COLD PCR technology, which preferentially enriches mutant DNA sequences in an excess of wild-type DNA.
The Munich-based firm will use the funds to bring its Pharos400 laser-based PCR molecular diagnostic platform to market.
The regulatory activity for the diagnostic platform follows ISO 13485:2003 certification in March. The firm is also planning a 510(k) submission to the FDA.
A new study has found that an antigen-based rapid diagnostic test for Ebola could be more reliable under certain circumstances than a recently approved RT-PCR assay for the virus.
It said the Hong Kong lab is the first in China to receive CAP accreditation.
In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.
A company says it can generate likenesses of people based on their genetic profiles.
IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.
At her blog, Sally Rockey dives into National Institutes of Health funding data.